BENGALURU (Reuters) – Serum Institute of India said on Wednesday that trials of AstraZeneca Plc’s COVID-19 vaccine candidate in the country is ongoing and has not faced any issues.
AstraZeneca said it has paused global trials, including large late-stage trials, of its experimental coronavirus vaccine due to an unexplained illness in a study participant.
“We can’t comment much on the U.K. trials,” Serum Institute said in a statement, adding “as far as Indian trials are concerned, it is continuing and we have faced no issues at all.”
(Reporting by Devjyot Ghoshal in New Delhi and Nallur Sethuraman in Bengaluru; Editing by Bernard Orr)
